Myriceric acid B is a potent HIV-1 entry inhibitor targeting gp41 and can serve as a lead compound for novel anti-HIV-1 drug development. It scavenges DPPH free radicals with an IC50 value of 21.8 µM and inhibits aromatase activity with an IC50 value of [incomplete data].
MPG, a 27-amino acid peptide compound, is derived from the fusion peptide domain of HIV-1 gp41 and the nuclear localisation sequence of SV40 large T antigen. As a potent delivery agent, MPG enables efficient and widespread transport of nucleic acids and oligonucleotides into cultured cells.